BCL2L1 and Thrombocytopenia: The combined Bcl-2/Bcl-xL inhibitor ABT-263 showed in clinical trials dose-limiting side effects with thrombocytopenia, attributed to inhibition of Bcl-xL, and leukocytopenia, due to Bcl-2 inhibition [39,40,41].